CoChat
Sign Up
Cited by 218T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersTelomeres, Telomerase, and Senescence

The DOI matches its Crossref record; 189 of the 191 references it cites were found in a registry or an index.

The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology

Open access
Huff, Wei X., Kwon, Jae Hyun, Henriquez, Mario, Fetcko, Kaleigh, Dey, Mahua·2019·International Journal of Molecular Sciences
DOI 10.3390/ijms20112810PMC PMC6600236
Open this paper in CoChat — free accountOpen PDF

Abstract

Functional, tumor-specific CD8+ cytotoxic T lymphocytes drive the adaptive immune response to cancer. Thus, induction of their activity is the ultimate aim of all immunotherapies. Success of anti-tumor immunotherapy is precluded by marked immunosuppression in the tumor microenvironment (TME) leading to CD8+ effector T cell dysfunction. Among the many facets of CD8+ T cell dysfunction that have been recognized—tolerance, anergy, exhaustion, and senescence—CD8+ T cell senescence is incompletely understood. Naïve CD8+ T cells require three essential signals for activation, differentiation, and survival through T-cell receptor, costimulatory receptors, and cytokine receptors. Downregulation of costimulatory molecule CD28 is a hallmark of senescent T cells and increased CD8+CD28− senescent populations with heterogeneous roles have been observed in multiple solid and hematogenous tumors. T cell senescence can be induced by several factors including aging, telomere damage, tumor-associated stress, and regulatory T (Treg) cells. Tumor-induced T cell senescence is yet another mechanism that enables tumor cell resistance to immunotherapy. In this paper, we provide a comprehensive overview of CD8+CD28− senescent T cell population, their origin, their function in immunology and pathologic conditions, including TME and their implication for immunotherapy. Further characterization and investigation into this subset of CD8+ T cells could improve the efficacy of future anti-tumor immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms20112810

Cites

189 of 189 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The priming and inactivation of CD8+ T cells. The interaction between TCRs and the peptide-MHC complex is the first step toward antigen-induced CD8+ T cell activation. This creates a site of extensive contact between T cells and APC, also called immunological synapses, where binding of CD28 on T cells with CD80/CD86 on APCs transduces a pivotal secondary costimulatory signal to complete the priming of naïve CD8+ T cells. In addition, CD4+ T helper (Th) cells when activated by DCs acquire not only the synapse-composed MHC class II and costimulatory molecules (CD54 and CD80), but also the bystander peptide-MHC-I complex from DC and become CD4+ Th-APCs, resulting in direct CD4+ T–CD8+ T cell interactions and subsequently delivery of CD40L signaling to CD40-expressing CD8+ T cells [21]. Furthermore, CD4 Th cells also secrete cytokines, such as IL-2, which promotes the differentiation of naïve CD8+ T cells into effector CTLs and memory CD8+ T cells. CTLs destroy antigen-specific target cells (such as cancer cells or viral infected host cells) via pathways including granule exocytosis, Fas ligand, and TRAIL-mediated apoptosis leading to tumor control or virus clearance and subsequent physiological T-cell inactivation as well as memory CD8+ T-cell formation [33]. Whereas pathological T-cell inactivation or conversion of CTL to CD8+ senescent T cells leads to tumor progression and virus replication.
Figure 1 The priming and inactivation of CD8+ T cells. The interaction between TCRs and the peptide-MHC complex is the first step toward antigen-induced CD8+ T cell activation. This creates a site of extensive contact between T cells and APC, also called immunological synapses, where binding of CD28 on T cells with CD80/CD86 on APCs transduces a pivotal secondary costimulatory signal to complete the priming of naïve CD8+ T cells. In addition, CD4+ T helper (Th) cells when activated by DCs acquire not only the synapse-composed MHC class II and costimulatory molecules (CD54 and CD80), but also the bystander peptide-MHC-I complex from DC and become CD4+ Th-APCs, resulting in direct CD4+ T–CD8+ T cell interactions and subsequently delivery of CD40L signaling to CD40-expressing CD8+ T cells [21]. Furthermore, CD4 Th cells also secrete cytokines, such as IL-2, which promotes the differentiation of naïve CD8+ T cells into effector CTLs and memory CD8+ T cells. CTLs destroy antigen-specific target cells (such as cancer cells or viral infected host cells) via pathways including granule exocytosis, Fas ligand, and TRAIL-mediated apoptosis leading to tumor control or virus clearance and subsequent physiological T-cell inactivation as well as memory CD8+ T-cell formation [33]. Whereas pathological T-cell inactivation or conversion of CTL to CD8+ senescent T cells leads to tumor progression and virus replication.CC BY · PubMed Central
Figure 2 Phenotypical and molecular changes in cellular senescence. A variety of intracellular (DNA damage, oncogenes, etc.) and/or extracellular signals (oxidative stress, chronic inflammation, etc.) can induce cellular senescence. Senescent cells exhibit numerous characteristics including but not limited to cell cycle arrest, increased nuclear p16 and p21 expression, increased lysosomal SA-β-gal activity, shortened telomere, and increased lipofuscin. Senescent cells can also present as a specialized secretory phenotype termed senescence associated secretory phenotype (SASP). Of particular interest, senescent immune cells present with lowered expression of CD28 and CD27 but heightened expression of CD57, KLRG-1, TIGIT, and other NK-cell associated surface receptors.
Figure 2 Phenotypical and molecular changes in cellular senescence. A variety of intracellular (DNA damage, oncogenes, etc.) and/or extracellular signals (oxidative stress, chronic inflammation, etc.) can induce cellular senescence. Senescent cells exhibit numerous characteristics including but not limited to cell cycle arrest, increased nuclear p16 and p21 expression, increased lysosomal SA-β-gal activity, shortened telomere, and increased lipofuscin. Senescent cells can also present as a specialized secretory phenotype termed senescence associated secretory phenotype (SASP). Of particular interest, senescent immune cells present with lowered expression of CD28 and CD27 but heightened expression of CD57, KLRG-1, TIGIT, and other NK-cell associated surface receptors.CC BY · PubMed Central
Figure 3 The heterogeneous functions of CD8+CD28− T cells. CD8+CD28− T cells originate from activated CD8+CD28+ T cells or from interaction with tolerogenic APCs. CD8+CD28− T cells exhibit both cytotoxic and immunoregulatory phenotypes and vary in pathological states such as across different cancer types or inflammatory/autoimmune conditions.
Figure 3 The heterogeneous functions of CD8+CD28− T cells. CD8+CD28− T cells originate from activated CD8+CD28+ T cells or from interaction with tolerogenic APCs. CD8+CD28− T cells exhibit both cytotoxic and immunoregulatory phenotypes and vary in pathological states such as across different cancer types or inflammatory/autoimmune conditions.CC BY · PubMed Central
Figure 4 The many facets of C8+ T cell dysfunction. In comparison to activated effector T cells, T cell anergy, exhaustion, and senescence can be distinguished by their unique expression or lack of expression of surface receptors as well as different levels of intracellular cytokines, such as IL-2.
Figure 4 The many facets of C8+ T cell dysfunction. In comparison to activated effector T cells, T cell anergy, exhaustion, and senescence can be distinguished by their unique expression or lack of expression of surface receptors as well as different levels of intracellular cytokines, such as IL-2.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 191 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Huff, W. X., Kwon, J. H., Henriquez, M., Fetcko, K., & Dey, M.
Affiliations
  • Indiana University School of Medicine (US)
  • University of Illinois Chicago (US)
Corresponding author
Dey, Mahua
ORCID
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2019-06-08
Volume
20
Issue
11
Pages
2810
ISSN
1422-0067 (ISSN-L)
DOI
10.3390/ijms20112810
PMC
PMC6600236
OpenAlex
W2948362628
Cited by
217
References
191
Citations by year
2026: 20 · 2025: 35 · 2024: 48 · 2023: 32 · 2022: 33 · 2021: 31 · 2020: 14 · 2019: 2
FWCI
1.73
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc-nd)
  • Purdue University Indianapolis (Indiana University) (submittedVersion, cc-by-nc-nd)
  • PMC
Funders
National Institutes of Health (K08NS092895)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
Keywords
CD8+CD28- T cells, T cell senescence, CD8+ cytotoxic T lymphocytes, tumor microenvironment, immunosuppression, T cell exhaustion, regulatory T cells, costimulatory molecules, telomere damage, anti-tumor immunotherapy, aging
MeSH terms
Immunosenescence, Animals, Humans, Immunotherapy, Neoplasms, CD28 Antigens, CD8-Positive T-Lymphocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review